[go: up one dir, main page]

MXPA03011324A - Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa. - Google Patents

Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa.

Info

Publication number
MXPA03011324A
MXPA03011324A MXPA03011324A MXPA03011324A MXPA03011324A MX PA03011324 A MXPA03011324 A MX PA03011324A MX PA03011324 A MXPA03011324 A MX PA03011324A MX PA03011324 A MXPA03011324 A MX PA03011324A MX PA03011324 A MXPA03011324 A MX PA03011324A
Authority
MX
Mexico
Prior art keywords
benzothienyl
inhibitors
novel
indole derivatives
alkyl
Prior art date
Application number
MXPA03011324A
Other languages
English (en)
Inventor
Perez Michel
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MXPA03011324A publication Critical patent/MXPA03011324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a compuestos de la formula general (I), (ver formula), en donde, en particular: W representa H, SO2R5, CO(CH2)nR5, (CH2)nR6, CS(CH2)nR5: X representa S o NH; Y representa (CH2)p, CO, (CH2)pCO, CH=CH-CO; Z representa un heterociclo, imidazol, bencimidazol, isoxazol, tetrazol, oxadiazoi, tiadazol, piridina, quinazolina, quinoxalina, quinolina, tiofeno; R1 representa COOR6, CONR6R7, CO-NH-CH(R6)-COOR7, CH2NR6R7, CH2OR6, (CH2)PR6, CH=CHR6; R2 representa en particular hidrogeno alquilo de C1-C10, un fenilo sustituido o no sustituido; R3 y R4 representan hidrogeno, alquilo de C1-C6; R5 representa un fenilo o naftilo sustituido o no sustituido; R6 y R7, identicos o diferentes, representan hidrogeno, alquilo de C1-C15, un heterociclo, un arilo; n representa 0 a 10; p representa 1 a 6.
MXPA03011324A 2001-06-06 2002-06-05 Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa. MXPA03011324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107384A FR2825706B1 (fr) 2001-06-06 2001-06-06 Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
PCT/FR2002/001905 WO2002098852A2 (fr) 2001-06-06 2002-06-05 Derives de benzothienyle ou d'indole et leur utilisation comme inhibiteurs de proteines prenyl transferase

Publications (1)

Publication Number Publication Date
MXPA03011324A true MXPA03011324A (es) 2004-05-05

Family

ID=8864002

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011324A MXPA03011324A (es) 2001-06-06 2002-06-05 Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa.

Country Status (10)

Country Link
US (1) US20040204417A1 (es)
EP (1) EP1395581A2 (es)
JP (1) JP2004532274A (es)
CN (1) CN1538969A (es)
BR (1) BR0210214A (es)
CA (1) CA2449771A1 (es)
FR (1) FR2825706B1 (es)
MX (1) MXPA03011324A (es)
WO (1) WO2002098852A2 (es)
ZA (1) ZA200309460B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
PT1397130E (pt) * 2001-06-20 2007-11-13 Wyeth Corp Derivados ácidos de indole substituído como inibidores de inibidor 1 do activador de plasminogénio (pai-1)
FR2839974B1 (fr) * 2002-05-24 2004-07-16 Pf Medicament Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament
PE20040609A1 (es) * 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
ATE331708T1 (de) * 2002-12-10 2006-07-15 Wyeth Corp Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1726191A (zh) * 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物
BR0316585A (pt) * 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
CN1726190A (zh) * 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050089936A1 (en) * 2003-10-23 2005-04-28 Jianping Cai Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid amides
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
CN1315839C (zh) * 2004-07-20 2007-05-16 中国科学院上海药物研究所 苯并噻吩［3,2－b］吲哚类衍生物、制备方法和用途
CA2577782A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
WO2006023866A2 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
JP2008536926A (ja) 2005-04-20 2008-09-11 メルク エンド カムパニー インコーポレーテッド ベンゾチオフェン誘導体
JP2008536924A (ja) 2005-04-20 2008-09-11 メルク エンド カムパニー インコーポレーテッド ベンゾチオフェンヒドロキサミン酸のカーバメート、ウレア、アミドおよびスルホンアミド置換誘導体
JP2009504762A (ja) * 2005-08-17 2009-02-05 ワイス 置換インドール類およびそれらの使用方法
EP2040690B1 (en) 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
EP2041072B1 (en) 2006-06-28 2013-09-11 Sanofi Cxcr2 antagonists
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.
WO2008000410A1 (en) 2006-06-30 2008-01-03 Sanofi-Aventis Cxcr2 inhibitors
FR2903312B1 (fr) * 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
CN102807540A (zh) * 2012-09-06 2012-12-05 无锡万全医药技术有限公司 一种新的5-氨基苯并呋喃-2-甲酸的制备方法
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018049200A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
MX2019010907A (es) 2017-03-15 2019-11-07 Metacrine Inc Agonistas del receptor x farnesoide, y usos de los mismos.
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Farnesoid x receptor agonists and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
SG11202102651SA (en) 2018-09-18 2021-04-29 Metacrine Inc Farnesoid x receptor agonists and uses thereof
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2021026180A1 (en) 2019-08-06 2021-02-11 Incyte Corporation Solid forms of an hpk1 inhibitor
WO2023139248A1 (en) * 2022-01-21 2023-07-27 Ecole Polytechnique Federale De Lausanne (Epfl) Inhibitors of acyl protein thioesterases against microbial infections
CN116554134A (zh) * 2023-05-15 2023-08-08 四川省医学科学院·四川省人民医院 苯并呋喃类化合物、其合成方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69915835T2 (de) * 1998-06-16 2005-03-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Imidazol-derivate

Also Published As

Publication number Publication date
JP2004532274A (ja) 2004-10-21
WO2002098852A2 (fr) 2002-12-12
CA2449771A1 (fr) 2002-12-12
FR2825706B1 (fr) 2003-12-12
WO2002098852A8 (fr) 2004-04-01
BR0210214A (pt) 2004-06-29
WO2002098852A3 (fr) 2003-04-17
EP1395581A2 (fr) 2004-03-10
US20040204417A1 (en) 2004-10-14
FR2825706A1 (fr) 2002-12-13
ZA200309460B (en) 2004-09-01
CN1538969A (zh) 2004-10-20

Similar Documents

Publication Publication Date Title
MXPA03011324A (es) Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa.
DK1260512T3 (da) Hidtil ukendte, cykliske amidderivater
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
EA200600509A1 (ru) Соединения пиримидотиофена
ATE326454T1 (de) Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
AR014448A1 (es) Compuesto de alanina, una composicion farmaceutica, uso del compuesto y proceso para la preparacion del compuesto
DK1323710T3 (da) Nitrogenholdige femleddede ringforbindelser
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
CO5271690A1 (es) Derivados de pirimidina
DE69927039D1 (de) Synthetische analoge des ecteinascidin-743
TR199902724T2 (xx) Dopamine D3 resept�rleri mod�lat�rleri olarak tetrahidroisokuinolin t�revleri.
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
DK2078007T3 (da) Ikk-beta-serin-threonin-proteinkinasehæmmere
NO20022976D0 (no) 2-(1H-indol-3yl)-2-okso-acetamider med antitumoraktivitet
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
TR200100852T2 (tr) 2-Fenilpiran-4-on türevleri
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
NZ504316A (en) Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists
CA2422807A1 (en) N-substituted benzothiophenesulfonamide derivatives
DE69910083D1 (de) Katecholhydrazon-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
EP1864977A4 (en) NOVEL CYCLIC COMPOUNDS HAVING A PYRIMIDINYLALKYLTHIO GROUP
MY134226A (en) 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
CA2479353A1 (en) N-substituted benzothiophenesulfonamide derivative
DE60239491D1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal